The Myeloproliferative Neoplasms Channel on VJHemOnc is an independent medical education platform, supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | The risk of heart failure in MPNs and the rate of CV-related readmissions following heart failure
Orly Leiva, MD, NYU Langone Health, New York City, NY, highlights the increased risk of heart failure in patients with myeloproliferative neoplasms (MPNs) and comments on a study that indicated an increased likelihood of cardiovascular (CV) and thrombotic readmissions in patients with myelofibrosis (MF) who have been hospitalized for heart failure. In JAK2-mutant mice, adverse cardiac remodeling has been observed, suggesting that patients with MPNs who harbor this mutation are at higher risk of experiencing heart failure. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
